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Purpose. To determine the in vivo biodistribution for differently
charged poly(amidoamine) (PAMAM) dendrimers in B16 melanoma
and DU145 human prostate cancer mouse tumor model systems.
Methods. Neutral (NSD) and positive surface charged (PSD) genera-
tion 5 (d 5 nm) PAMAM dendrimers were synthesized by using
3H-labeled acetic anhydride and tested in vivo. Dendrimer deriva-
tives were injected intravenously, and their biodistribution was de-
termined via liquid scintillation counting of tritium in tissue and ex-
cretory samples. Mice were also monitored for acute toxicity.
Results. Both PSD and NSD localized to major organs and tumor.
Dendrimers cleared rapidly from blood, with deposition peaking at
1 h for most organs and stabilizing from 24 h to 7 days postinjection.
Maximal excretion occurred via urine within 24 h postinjection. Nei-
ther dendrimer showed acute toxicity.
Conclusions. Changes in the net surface charge of polycationic
PAMAMs modify their biodistribution. PSD deposition into tissues is
higher than NSD, although the biodistribution trend is similar. High-
est levels were found in lungs, liver, and kidney, followed by those in
tumor, heart, pancreas, and spleen, while lowest levels were found in
brain. These nanoparticles could have future utility as systemic bio-
medical delivery devices.
KEY WORDS: biodistribution; melanoma; PAMAM dendrimers;
prostate cancer; tritiated nanoparticles.
INTRODUCTION
We report the biodistribution of generation 5 poly(ami-
doamine) (PAMAM) dendrimer derivatives in a mouse tu-
mor model system. PAMAM dendrimers are commercially
available macromolecules that can efficiently be used (1–6) as
delivery vehicles for oligonucleotides, antisense oligonucleo-
tides, and as probes for oligonucleotide arrays (6–8). PAMAM
dendrimers are being investigated for drug delivery, gene
therapy, and imaging systems (4–6,9–15).
The evaluation of drug delivery, including dendrimers
carrying a targeting moiety attached to their surface, requires
the knowledge of the biodistribution of the same carrier den-
drimers minus the specific targeting groups. It is expected that
size and charge will change the interaction of dendrimers with
the cell membrane, thus influencing the nonspecific uptake of
these carrier molecules. Generation 4 PAMAMs do not have
the necessary dendritic properties to be an effective drug car-
rier (1,2) whereas generation 6 and 7 PAMAM materials are
still too expensive. Generation 5 PAMAM dendrimers have
successfully been used in several medical research areas
(1,2,4–6,9,12–14), but the role of their charge distribution has
not been studied.
Earlier biodistribution studies of PAMAM dendrimers
have been carried out with full generation PAMAM dendrim-
ers that were radiolabeled by partially quaternizing the amine
termini using 14C containing methyl iodide (16). Commercial
Starburst PAMAM dendrimers are a mixture of macromol-
ecules containing minor imperfections, which reduces the to-
tal number of available terminal groups (17). Labeling PAMAM
Starbursts with 13C iodomethane results in a mixture of quat-
ernized and unquaternized dendrimer end groups in which
the radiolabeled macromolecules carry permanent positive
charges whereas the charge of unlabeled species depends on
the pH. In this mixture, the biodistribution of quaternized
(i.e., radiolabeled  charged) macromolecules could be dif-
ferent from the biodistribution of unquaternized molecules
because the terminal primary amines are not protonated at
biologic pH values and thus are not charged (18). If biodis-
tribution depends on the dendrimer charge, this labeling
method may lead to data in which the distribution of labeled
molecules is different from the overall distribution of the den-
drimers.
The starting PAMAM_E5.NH2 proved to be toxic to the
mice (12). We hypothesized that decreasing the surface
charge of PAMAM dendrimers toward neutral would reduces
in vivo toxicity. This can be achieved by acetylation (14).
Transformation of the primary amine groups with an anhy-
dride is a very straightforward and quantitative reaction that
results in acetamide termini (19). We synthesized a fully
acetylated dendrimer, with a neutral surface, and a partially
acetylated product, with a partially positive surface charge
(both products had differing net positive overall charge due to
the partially protonated internal tertiary nitrogen atoms). We
examined the biodistribution and the toxicity of 5 nm tritiated
PAMAM dendrimer nanoparticles that have different surface
charges [neutral surface dendrimer (NSD) and positive sur-
face dendrimer (PSD)] in normal and tumor tissues.
MATERIALS AND METHODS
Synthesis and Characterization of Tritium-Labeled
PAMAM Dendrimers
Chemicals (acetic anhydride, pyridine, MeOH, HCl,
NaOH) were purchased from Aldrich (Milwaukee, WI,
USA). Solvents were HPLC grade. PAMAM_E5.NH2, eth-
ylenediamine (EDA) core, generation five, amine-terminated
poly(amidoamine) (PAMAM) dendrimer was purchased
from Dendritech (Midland, MI, USA) in methanol solution
and was further purified by dialysis using reconstructed cel-
lulose membranes (Pierce, molecular weight cut-off
(MWCO)  10 kDa (kilodaltons) to remove potential small
molecular contamination such as excess solvent, salts, and
trailing generations. The materials were lyophilized and ana-
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lyzed by 1H NMR, 13C NMR, mass spectrometry, high pres-
sure liquid chromatography (HPLC), polyacrylamide gel
electrophoresis (PAGE), and capillary electrophoresis (CE)
to ensure purity and homogeneity of the final products. Theo-
retically, a PAMAM_E5.NH2 molecule has a molecular
weight of 28,825 Da and contains 128 primary amine termini.
The practical number of terminal amines for the particular
PAMAM dendrimer we used was determined by acid-base
titration and was found to be n  110. The molecular weight
of the dendrimer was 26,200 Da (as determined by size ex-
clusion chromatography; SEC).
Tritium-labeled acetic anhydride (100 mCi) was pur-
chased from ICN Biomedicals (Irvine, CA, USA) and mixed
with a known amount of absolute acetic anhydride before use
to approach a precalculated specific activity in the products
necessary to carry out precise tritium measurements. Label-
ing of PAMAM was performed via acetylation at room tem-
perature in absolute dimethylsulfoxide in the presence of 50
molar% excess of absolute pyridine for one day (Fig. 1). The
resulting products were purified by dialysis against distilled
water using reconstructed cellulose membranes (MWCO 
10 kDa) while monitoring the diminishing tritium activity
in the water. Labeled polymer products were filtered on 0.2
m Teflon filters and stored as aqueous solutions at 4°C in
sealed vials. Purity and integrity of acetylated dendrimers
were checked by PAGE, which indicated no degradation. De-
gree of acylation was determined from the complete mass
balance of the total tritium involved. The final measured ac-
tivity and degree of average substitution for dendrimers
PAMAM_E5.(NHCOCH3)110 (or NSD) was 10.27 mCi/g and
for PAMAM_E5.(NH2)44 (NHCOCH3)66 (or PSD) was 17.01
mCi/g. Residual free mobile tritium was <0.3% of the total
activity at the time of the biodistribution experiment. Triti-
ated dendrimers were repeatedly purified by dialysis on a
10 kDa MWCO membrane after 11 months. Exchange of tri-
tium with water protons during storage resulted in a 10%
decrease in activity in this period of time.
Instrumentation
Analysis of PAMAM dendrimers by PAGE was per-
formed on a Micrograd vertical electrophoresis system with a
commercial power supply (Model 500/200; BioRad, Hercules,
CA, USA). Electrophoresis experiments were performed on
10 × 8 cm gels in a vertical electrophoresis unit (Model Pro-
tean I; BioRad) using precast 4–20% gradient express gels for
PAGE (ISC BioExpress). PAGE separations typically re-
quired 50 min at 200 V in Tris-Glycine (TG) buffer (pH 
8.3). Developed gels were stained with 0.025% Coomassie
blue R-250 overnight.
The CE instrument was purchased from Agilent Tech-
nologies (Waldbronn, Germany) and was equipped with an
on-capillary UV diode-array detection system. Unmodified
quartz capillaries (100 m ID × 78.5 cm) were obtained from
Polymicro Technologies (Phoenix, AZ, USA) and silanized.
Samples were introduced by hydrodynamic injection, separa-
tion voltage was 20 kV, and the capillary temperature was
40°C for all the separations.
Potentiometric titration was carried out manually, using
an Orion Model 230A pH meter (Thermo Electron Corp.,
Woburn, MA, USA) and an Orion Sure-Flow micropH elec-
trode at room temperature. Approximately 50 mg of
PAMAM dendrimer was dissolved in 10 ml of DI water
and titrated in 0.1 ml increments with 0.1 N HCl. A 0.1 N NaOH
solution was used for back-titration. The number of primary
amines was determined from the evaluation of both titration
data.
Animal Handling and Tumor Cell Line
Animal work was conducted in the animal facility at Uni-
versity of Michigan Medical Center in accordance with fed-
eral, local and institutional guidelines. Experiments adhered
to the Guide for the Care and Use of Laboratory Animals
(NIH Publication No. 85-23, revised 1985).
Six- to 10-week-old male C57BL/6J mice or 30-week-old
male athymic nude (nu/nu) mice were used (Jackson Labs,
Bar Harbor, ME, USA). They were caged in a specific patho-
gen-free barrier facility as groups of five or less and fed ad
libitum with Laboratory Autoclavable Rodent Diet 5010
(PMI Nutrition International, St. Louis, MO, USA). For ex-
cretion studies, five animals were housed in metabolic rodent
Fig. 1. Structure of poly(amidoamine) dendrimers. (A) Chemical
structure of generation 1, ethylenediamine core, amine-terminated
PAMAM. (B) Computer model of a generation five macromolecule
(courtesy of Inhan Lee, University of Michigan). Schemes of acety-
lation of PAMAM dendrimers: Scheme A, Scheme of full acetylation
based on theoretical numbers. Scheme B, Scheme of partial acetyla-
tion based on experimentally determined values. The asterisks de-
note tritiated hydrogen atoms.
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cages (Nalgene, Rochester, NY, USA). Anesthesia was via
isoflurane inhalation (Abbott Laboratories, North Chicago,
IL, USA) prior to surgical procedures. A restrainer (Braintree
Scientific Inc., Braintree, MA, USA) was used for tail-vein
injections. Euthanasia was with carbon dioxide.
The isogenic B16F10 melanoma cell line was maintained
by serial passage within C57BL/6J mice as described previ-
ously, with 26 gauge as the smallest needle (20). For biodis-
tribution studies, the B16F10 tumor cells (freshly isolated
from carrier mice) were injected subcutaneously into the dor-
sal surface of 8- to 10-week-old C57BL/6J mice (30 g) and
grown until the tumors reached a size of greater than 500 mm3.
The DU145 human prostate carcinoma cells were grown
in culture, and 1.5 × 106 cells were injected subcutaneously
into one flank of each athymic nude (nu/nu) mouse (25 g).
These slower growing tumors were grown to 500 mm3.
Biodistribution Studies and Dendrimer Quantification
When tumors were >500 mm3, B16 melanoma-bearing
mice were injected via tail vein with 500 l (8.8 g of PSD and
17.5 g of NSD) of nanoparticle solution in PBS (Dulbecco’s
phosphate buffered saline, Sigma-Aldrich, St. Louis, MO,
USA). At 5 min, 1 h, and 1, 4, and 7 days postinjection, mice
were euthanized and the organs (lung, heart, liver, kidney,
spleen, pancreas, tumor, and brain) were dissected and
weighed. At all time points, blood samples were collected via
cardiac puncture. Typically, each sample of tissues collected
ranged between 50 mg to 200 mg. Three to eight mice per
nanoparticle per time point were studied. Athymic nude (nu/
nu) mice bearing DU145 flank tumors that were at least 500
mm3 were intravenously injected with PSD, and tissues were
harvested at 5 min, 1 h, and 1, 4, and 7 days after injection.
Using metabolic cages, urine and feces were collected at
2, 8, and 24 h postinjection and then once every day for up to
7 days after injection of either dendrimer. Some feces pellets
did not roll into the collection tube and absorbed urine (re-
ported as mixed excreta).
To ensure accurate measurement of the low energy beta
radiation emitted by tritium, all harvested samples were com-
pletely dissolved. One milliliter of “Solvable” solution (Pack-
ard, Downers Grove, IL, USA) was added per sample, and
the samples were shaken at 50–55°C overnight. They were
subsequently decolorized with 200–300 l of 30% hydrogen
peroxide (Sigma-Aldrich). The amount of tritium per sample
was determined via liquid scintillation counting using 10 ml
Hionic fluor (Packard Bioscience, Downers Grove, IL, USA)
per sample. The counts per minute obtained per sample were
Table I. Intraorgan Biodistribution of PAMAM_E5.(NH2)44
(NHCOCH3)66 Positive Surface Dendrimer (PSD) in Liver
Mouse
number
1 h 1 Day 4 Day 7 Day
1 2 1 2 1 2 1 2
Mean 0.107 0.077 0.078 0.068 0.066 0.053 0.092 0.070
SD 0.013 0.006 0.003 0.002 0.003 0.002 0.003 0.004
Representative data from two B16 melanoma-bearing mice are
shown. Seven independent samples from each mouse’s liver were
collected. The mean (±SD) microcuries of tritium per gram of tissue
recovered are shown. The liver intraorgan distribution was seen to be
homogenous.
Fig. 2. Biodistribution in C57BL/6J mice (B16 melanoma model),
depicted as percent injected dose recovered per gram of organ (%
ID/g ± SD) of tritiated dendrimers (n  4 to 8). (A, B) Positive
surface dendrimers (PSD). (C, D) Neutral surface dendrimers
(NSD). (E) Tumor uptake for PSD and NSD. (A magnified depiction
of PSD distribution in liver, kidney and pancreatic tissues is shown as
an inset in A.)
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corrected for efficiency of counting and used to derive the
number of disintegrations per minute and thus radioactivity
(microcuries) per sample. The radioactivity per milligram
(Ci/mg) recovered from tissues was normalized to the
amount of tritium injected per respective mouse (i.e., the in-
jected dose). The results were then expressed as a percentage
of the injected dose per gram of tissue (% ID/g). Thus, the
resultant organ and tumor biodistribution data are directly
comparable between mice and different dendrimer nanopar-
ticles.
RESULTS
Synthesis of Tritium-Labeled Dendrimers
We successfully synthesized and characterized tritiated
PAMAM dendrimer based organic nanoparticles with differ-
ent surface charges (positive and neutral). The dendrimers
were modified using 3H labeled acetic anhydride in which the
tritium is covalently bound in the methyl groups thus provid-
ing stable labels. Tritium facilitated manipulations during
in vivo experiments. Labels are on the neutral acetamide ter-
mini and therefore do not change the charge-dependent re-
sponse, while reflecting the true dendrimer distribution. The
varying degree of acylation may lead to varying levels of tri-
tium activity, but this complication can be circumvented by
comparing the measured values to the total injected dose.
Regulation of surface charge and labeling was achieved via
acetylation by partially or fully reacting terminal primary
amine groups of the PAMAM molecules. This synthetic step
served two purposes: 1) toxicity caused by the polyamine
character (terminal primary amine groups of PAMAM are
positively charged at biologic pH values) was eliminated, and
2) stable tritium labels for the nanoparticles were formed.
Radioactive labeling of dendrimers by 3H-containing acetic
anhydride allowed proper and accurate quantification of the
PAMAM derivatives for the true in vivo biodistribution as a
function of time, because the labels were introduced as ter-
mini that did not carry a charge. Partial acetylation of the
terminal amine groups produced polycationic dendrimers
with decreased but adjustable surface charge, and increasing of
the degree of acetylation decreased the surface positive charges.
Intraorgan Distribution and Accuracy of Injection
In order to determine if the vascular delivery of dendrim-
ers could achieve homogenous intraorgan distribution, the
tritium in seven samples (obtained from multiple lobes of the
liver) was measured. Both PAMAM dendrimers were distrib-
uted throughout the liver with very low standard deviation
between liver samples at all time points tested (Table I). Ho-
mogenous dendrimer uptake within the liver confirmed that a
uniform distribution within vascular organs occurred after in-
travenous administration of dendrimers. Also, comparable
dendrimer levels in the livers of different mice showed the
reproducibility and accuracy of systemic delivery via tail vein
injections.
Organ and Tumor Distribution of Positive and Neutral
Surface Dendrimers
Tritiated PSDs and NSDs showed no preferred distribu-
tion into any tissue tested. Both nanoparticles localized to all
major organs tested, as well as to tumor tissue, and were
recoverable within 5 min postinjection. For most tissues, fol-
lowing an initial rapid clearance during the first day postin-
jection, the nanoparticles were maintained at a relatively
stable level with a very slow decline over time (Fig. 2). Within
the first hour postinjection, both nanoparticles exhibited the
highest uptake in the lungs, kidney, and liver (PSD, 27.9–
6.08% ID/g; NSD, 5.3–2.86% ID/g). Levels in tumor, heart,
spleen, and pancreas followed this (PSD, 3.26–2.64% ID/g;
NSD, 3.44–0.92% ID/g), while the least amount of dendrim-
ers was deposited into brain tissue (PSD, 0.6% ID/g; NSD,
0.39% ID/g).
Both dendrimers cleared rapidly from blood, with 5 min
(20.6, 21.6), 1 h (14.3, 9.9), 1 day (1.7, 0.9), 4 days (0.3, 0.1),
7 days (0.2, 0.1) %ID/g levels for (PSD, NSD), respectively.
Fig. 3. Ratio of the percent injected dose per gram of organ (% ID/g) of positive surface dendrimer (PSD) relative
to that of the neutral surface dendrimer (NSD) in tissues of C57BL/6J mice (B16 melanoma model). The bars show
mean ratios and error bars show total standard deviation.
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Most organs showed maximum uptake within 5 min, except
tumor and pancreas (maxima at 1 h). Deposition of positive
surface dendrimers are higher than neutral surface dendrim-
ers within 1 h postinjection in all organs and tissues analyzed,
including tumor tissue (Fig. 3).
The dendrimers were excreted via both urine and feces
(Fig. 4). A total of 48.3% of NSD and 29.6% of PSD were
excreted via urine over 7 days. Within the first 2 h, urinary
NSD excretion was more than 3-fold that of PSD, but at later
sampling points the daily excretion of both dendrimers was
equivalent. Dendrimers were excreted via feces to a much
lesser extent, with a total of 5.41% of NSD and 2.96% of PSD
recovered over 7 days (Fig. 4). Thus, the dendrimers were
excreted mainly via urine with a significant amount of urinary
excretion occurring within 24 h postinjection.
Because tumor-bearing mice would die due to their tu-
mor-burden, long-term biodistribution studies of NSD and
PSD were done with normal (non-tumor-bearing) mice. Five
mice were injected with either NSD or PSD, and organs were
harvested 12 weeks after dendrimer injection. The dendrim-
ers were detectable in all organs tested (Table II). This dem-
onstrated that the nanoparticles could distribute to all organs
tested and remain there at relatively stable levels for at least
12 weeks. The mice appeared healthy at that time as well.
Fig. 4. Excretion of positive surface dendrimers (PSD) and neutral surface dendrimers (NSD) via urine, feces, and
mixed excreta (A, B, and C respectively) at time points indicated. Mixed excreta comprise urine and fecal materials
that were inseparable. The data obtained from B16F10 melanoma mouse model (n  5) is presented as a percentage
of injected dose excreted per mouse.
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Confirmatory Biodistribution in a Human Prostate Cancer
Mouse Xenograft Model System
To verify the biodistribution results from B16 melanoma
bearing mice, we used an unrelated tumor model system.
DU145 human prostate tumor-bearing mouse xenograft
(athymic nu/nu) and non-tumor-bearing athymic nude (nu/nu)
mice were injected intravenously with PSD. Organs and tu-
mor tissue were harvested at 1 h, 1- and 4-day time points
after injection and analyzed for tritium content (see “Mate-
rials and Methods”). The results were expressed as the per-
centage of the injected dose per gram of tissue (% ID/g). The
trends of PSD distribution in DU145 prostate tumor-bearing
mice and the non-tumor-bearing mice were similar to those
observed in the B16 melanoma bearing mice. The only sig-
nificant difference between the two tumor models was a faster
clearance of the PSD in spleens of the DU145 tumor bearing
mice (Fig. 5). This indicated that the dendrimer biodistribu-
tions are generally applicable, with only minor mouse tumor
model effects.
Biological Safety of Dendrimers
There was no acute in vivo toxicity noted from the PSD
and NSD dendrimer injections. Five mice were injected with
500 l each of NSD (17.5 g) and another five mice with PSD
(8.8 g). These mice along with five uninjected control mice
were monitored for 12 weeks, noting their weight, signs of
dehydration, weakness, lethargy, change in activity, and any
inability to eat or drink. The dendrimer-injected groups of
mice showed a steady weight gain for 10 days after which the
weights were maintained, similar to the control group of mice.
No difference was observed between the control group and
the dendrimer injected groups of mice for the toxicity param-
eters monitored.
DISCUSSION AND CONCLUSIONS
It had previously been reported that PAMAM den-
drimer toxicity is dose- and generation-dependent, with intra-
peritoneal injections of generation five or smaller dendrimers
appearing to be nontoxic in vivo (16,21). Previous studies
were conducted with normal (non-tumor-bearing) mice, in a
few tissues, and over a short time period. It is particularly
important to evaluate these novel nanoparticles over a pro-
longed time period, and with intravenous injection, as this is
what will occur with human therapy. Both positive surface
and neutral surface acetylated PAMAM dendrimers de-
scribed in this study were placed at pH 7.4 and systemically
administered to the mice. The tritiated nanoparticles were not
acutely toxic in tumor bearing mice (7 days). In non-tumor-
bearing injected mice, there were no deleterious effects from
the nanoparticles for up to 12 weeks. The partial or full acety-
lation of the surface amine groups and physiologic pH adjust-
ment renders the PAMAM_E5 dendrimer nanoparticles
physiologically tolerable when injected intravenously.
Two types of dendrimer nanoparticles were successfully
studied. While both were 5 nm in size, they differed in their
surface charge (intentionally modulated to be either neutral
or positive). For 5-nm-diameter PAMAM dendrimers, sur-
face charge differences affected the relative deposition of the
PAMAM dendrimers, rather than the distribution into organs
tested at any given time point, with the PSD showing higher
deposition overall.
Neither dendrimer localized selectively to tumor tissue,
with distribution to all organs tested. Following an initial rapid
clearance during the first day postinjection, nanoparticles
were maintained at a relatively stable level in every tissue,
with a very slow decline over time. Excretory analyses re-
vealed that the dendrimers were excreted via both urine and
feces with maximal excretion occurring via urine within the
first 24 h. Urinary NSD amounts excreted exceeded those of
PSD by more than 3-fold within 2 h postinjection. This is
consistent with more PSD taken up by tissues, and therefore
less excreted.
The fact that these nanoparticles distribute into every
tissue tested and remain relatively stable over prolonged pe-
riods may prove useful in the future for systemic in vivo de-
Table II. Long-Term Biodistribution of Dendrimers
NSD PSD
Blood 0.02 ± 0.00 0.09 ± 0.01
Lungs 0.13 ± 0.04 0.17 ± 0.08
Heart 0.17 ± 0.02 0.16 ± 0.07
Liver 0.39 ± 0.12 0.37 ± 0.16
Spleen 0.55 ± 0.21 0.52 ± 0.31
Pancreas 0.20 ± 0.03 0.33 ± 0.17
Kidney 0.38 ± 0.10 1.09 ± 0.29
Brain 0.07 ± 0.01 0.11 ± 0.01
Biodistribution of neutral surface dendrimer [NSD, PAMAM_E5.
(NHCOCH3)110] and positive surface dendrimer [PSD,
PAMAM_E5.(NH2)44 (NHCOCH3)66] at 12 weeks after intrave-
nous injection is shown. The data are from non-tumor-bearing mice
(to be able to obtain a longer time point) and are presented as %
injected dose/gram ± standard deviation.
Fig. 5. Biodistribution in athymic nude (nu/nu) mice (DU145 human
prostate cancer xenograft model) depicted as percent injected dose
recovered per gram of organ (% ID/g ± SD) of PSD. (A, B) tumor-
bearing mice (n  3).
3H Dendrimer Nanoparticle Organ/Tumor Distribution 481
livery of agents (e.g., DNA or drugs) to numerous tissues.
Also, because biodistribution in both mouse tumor models
was very similar, this mode of systemic dendrimer delivery
promises to be generally applicable.
Chemically, it is important to note that practical grade
PAMAM dendrimers are not a set of identical, pure, and
discrete macromolecules because of their polymer character
and minor structural deviations (17). Dendrimers, being spheri-
cal polyfunctional macromolecules, are better described by
their average molecular mass and molecular mass distribu-
tion. Thus, when these macromolecules are reacted to form a
derivative, a distribution of substituents will be produced,
instead of identical macromolecules with the same degree of
substitution (22).
Radiolabeling allows conclusions about the presence of
materials by determining the presence of a labeled subset
usually by measuring the overall radiation. As labeling of
every single molecule would result in enormous level of ra-
dioactivity, usually only a subset of molecules carries the ra-
dioactive label. This implies that a certain property of the
subset represents the whole population. Measuring the aver-
age radioactivity in a sample thus represents the distribution
of the whole population only if the properties of the measured
subset of labeled molecules are identical with the unlabeled
ones. Covalent radiolabeling of PAMAM dendrimers with
tritium-containing acetic anhydride results in controlled
modulation of macromolecular surface charge and fully main-
tains the chemical characteristics of the nanoparticles reacted
with unlabeled reactants.
Following intravenous administration, the PSDs and
NSDs were carried via the circulatory system to different
parts of the body. We postulate that while the majority of
nanoparticles are cleared and excreted, some are deposited
into microvasculature of various organ tissues and internal-
ized by the endothelium or cells adjacent to the endothelium.
This hypothesis is supported by another study we carried out,
in which a 5-nm nonradioactive gold complexed amine sur-
face dendrimer nanoparticle was synthesized and tested. In
those studies, the gold nanocomposite solution was directly
injected into dorsal B16 melanoma tumors (1) or DU145
prostate tumors (12), and transmission electron microscopy of
tumor tissue indicated that the gold nanocomposites rapidly
leave the interstitium and are internalized by the cells (1,12).
Tumor growth and successful metastases is dependent on
tumor angiogenesis, that is, the formation of new microvessels
(23,24). Now that accurate measurement and toxicity tests of
the nanoparticles have been demonstrated, in future studies
we plan to design nanomolecular devices that localize to tu-
mor cells by exploiting the differences between normal and
tumor microvasculature. The tumor microvasculature is
leakier then the normal microvasculature (25–29). It has been
shown that extravasation of smaller PAMAM dendrimers
through the normal microvasculature of hamster muscle is
dependent on size and molecular weight (30). Therapies tar-
geted to tumor microvasculature or to the angiogenic process
are attractive because they are inherently applicable to all
tumors. In conjunction with traditional therapy, anti-angio-
genic approaches could help control and/or treat metastases.
The biodistribution and biological evaluation studies pre-
sented here are an important first step in this process.
This study demonstrates the feasibility of using tritiated
PAMAM dendrimers to analyze the effect of nanoparticle
charge on in vivo biodistribution in mouse tumor model sys-
tems and showed the low toxicity of these nanoparticles. We
were able to determine that the dendrimers (d  5 nm)
cleared rapidly from the blood, distributed to and remained
stable in all organs and tissues tested for at least 7 days in
tumor-bearing mice. We also found that PSD deposition into
B16 melanoma tumor tissue is almost 1.5 fold as much as that
of the NSD within 1 day postinjection. Results were similar in
two very different tumor model systems. The ability to build,
modulate the surface, and measure these devices accurately
over time will have significant implications for the imaging
and treatment of variety of local and metastatic tumors.
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